NASDAQ:EVFM Evofem Biosciences (EVFM) Stock Price, News & Analysis $0.01 +0.00 (+3.09%) As of 09:57 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Evofem Biosciences Stock (NASDAQ:EVFM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evofem Biosciences alerts:Sign Up Key Stats Today's Range$0.0098▼$0.0150-Day Range$0.0089▼$0.0152-Week Range$0.0061▼$0.0150Volume785,769 shsAverage Volume406,182 shsMarket Capitalization$1.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evofem Biosciences is a clinical‐stage biotechnology company based in San Diego, California, specializing in women’s sexual and reproductive health. Founded in 2013 as a spin-out of the Scripps Research Institute, the company is focused on developing non-hormonal, on-demand products that address unmet needs in contraception and the prevention of sexually transmitted infections. The company’s lead commercial product, Phexxi, is an FDA-approved, non-hormonal vaginal gel that maintains the vagina’s natural pH to reduce the risk of unintended pregnancy. Phexxi offers an alternative to hormonal birth control by using a proprietary combination of lactic acid, citric acid and potassium bitartrate. Beyond its marketed offering, Evofem maintains a research and development pipeline that includes additional vaginally administered candidates aimed at preventing chlamydia and gonorrhea, reflecting its commitment to broadening women’s health options. Evofem Biosciences conducts its primary operations in the United States and engages with healthcare providers, payers and distribution partners to support product adoption and access. The company is led by a management team with experience in biotechnology commercialization and women’s health, and it continually explores strategic collaborations to advance its novel therapeutic platform and expand its geographic reach.AI Generated. May Contain Errors. Read More Evofem Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreEVFM MarketRank™: Evofem Biosciences scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Evofem Biosciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Evofem Biosciences have been sold short.Short Interest Ratio / Days to CoverEvofem Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evofem Biosciences has recently increased by 50.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvofem Biosciences does not currently pay a dividend.Dividend GrowthEvofem Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.90 Percentage of Shares Shorted0.00% of the outstanding shares of Evofem Biosciences have been sold short.Short Interest Ratio / Days to CoverEvofem Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evofem Biosciences has recently increased by 50.00%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.48 News SentimentEvofem Biosciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Evofem Biosciences this week, compared to 0 articles on an average week.Search Interest3 people have searched for EVFM on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evofem Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Evofem Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.22% of the stock of Evofem Biosciences is held by institutions.Read more about Evofem Biosciences' insider trading history. Receive EVFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVFM Stock News HeadlinesEvofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder MeetingSeptember 9 at 3:43 PM | finanznachrichten.deEvofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder MeetingSeptember 9 at 9:28 AM | prnewswire.comNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.September 10 at 2:00 AM | Paradigm Press (Ad)Evofem Biosciences Updates Merger Agreement with AditxtAugust 26, 2025 | msn.comIllinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed LawAugust 21, 2025 | prnewswire.comEvofem says FDA Orange Book lists patent for Solosec treatmentAugust 19, 2025 | msn.comFDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and TrichomoniasisAugust 19, 2025 | prnewswire.comEvofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business UpdateAugust 14, 2025 | prnewswire.comSee More Headlines EVFM Stock Analysis - Frequently Asked Questions How have EVFM shares performed this year? Evofem Biosciences' stock was trading at $0.0099 at the beginning of 2025. Since then, EVFM shares have increased by 1.0% and is now trading at $0.01. How were Evofem Biosciences' earnings last quarter? Evofem Biosciences, Inc. (NASDAQ:EVFM) released its quarterly earnings data on Friday, June, 16th. The biotechnology company reported ($1.85) EPS for the quarter, topping the consensus estimate of ($15.00) by $13.15. The biotechnology company earned $5.81 million during the quarter. Evofem Biosciences had a negative net margin of 46.42% and a negative trailing twelve-month return on equity of 91.97%. When did Evofem Biosciences' stock split? Shares of Evofem Biosciences reverse split on Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Evofem Biosciences? Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evofem Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F). Company Calendar Last Earnings6/16/2023Today9/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVFM CIK1618835 Webwww.evofem.com Phone(858) 550-1900Fax844-828-2010Employees120Year Founded2007Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$52.98 million Net Margins-46.42% Pretax Margin-46.42% Return on Equity-91.97% Return on Assets-61.93% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.09 Sales & Book Value Annual Sales$11.39 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($2.64) per share Price / Book0.00Miscellaneous Outstanding Shares118,656,000Free Float113,118,000Market Cap$1.15 million OptionableNot Optionable Beta-1.11 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:EVFM) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
